心力衰竭中的心脏与脏相互作用:从最近的治疗进展中获得的见解
Kevin Damman1, Jeffrey Testani2
1University of Groningen, Department of Cardiology, University Medical Center Groningen, Hanzeplein 1, Groningen 9713GZ, The Netherlands.
Cardiovascular research
|June 26, 2023
概括
新的药物类别,包括SGLT2抑制剂和GLP-1RA,在预防和治疗心力衰竭方面表现有前途,特别是在患有糖尿病和脏疾病的高风险患者中.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
背景情况:
- 心力衰竭显著影响生活质量,死亡率和医疗保健成本.
- 对心力衰竭的有效预防和治疗策略至关重要.
- 心血管疾病的进展往往导致心力衰竭.
研究的目的:
- 评估新型治疗剂在治疗心力衰竭中的作用.
- 评估SGLT2i,GLP-1-RAs和MRAs在心脏病中的有效性.
- 探索这些药物对心血管和脏结果的影响.
主要方法:
- 专注于患有糖尿病,慢性病和/或心力衰竭的高风险患者群体.
- 对-葡萄糖辅运输体2抑制剂 (SGLT2i) 临床数据的分析.
- 综述了涉及葡萄糖类1受体激动剂 (GLP-1-RAs) 和非类固醇矿物质皮质体受体对抗剂 (MRAs) 的研究.
主要成果:
- 在所有心力衰竭亚型中,SGLT2i已经证明了其有效性.
- GLP-1-RAs在降低糖尿病患者心血管事件方面是有效的.
- 这些药物类改善心血管和脏终点在心脏脏连续.
结论:
- 包括SGLT2i,GLP-1-RA和MRA在内的新型疗法正在推进心力衰竭治疗.
- 这些药物为患有心脏病和糖尿病的患者提供了显著的好处.
- 进一步的研究正在进行中,以充分阐明MRAs和GLP-1-RAs在已确定的心力衰竭中的作用.
更多相关视频
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.6K
10:25Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury
Published on: August 30, 2011
18.2K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
01:30Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
01:22Heart Failure Drugs: Diuretics
425
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
425
01:29Cardiomyopathy V: Interprofessional Care
18
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
18
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:26Heart Failure Drugs: Inotropic Agents
640
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
640